P07900 (HS90A_HUMAN) Homo sapiens (Human)
Heat shock protein HSP 90-alpha UniProtKBInterProSTRINGInteractive Modelling
732 aa; Sequence (Fasta) ; (Isoform 2);
3 identical sequences: Ailuropoda melanoleuca: A0A7N5JNB0; Homo sapiens: K9JA46; Heterotrigona itama: A0A6V7GW39
It is possible new templates exist for this target since these models were created.
Available Structures
339 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Cryo-EM structure of the GR-Hsp90-FKBP51 complex |
Heteromer P04150; Q13451; | 2×ATP; 2×MG; 1×DEX; | ||||
| Assess | ||||||
| Cryo-EM structure of the GR-Hsp90-FKBP52 complex |
Heteromer P04150; Q02790; | 2×ATP; 2×MG; 1×DEX; | ||||
| Assess | ||||||
| Atomic cryoEM structure of Hsp90-Hsp70-Hop-GR |
Heteromer P04150; P0DMV8; P31948; | 2×ADP; 2×MG; 2×K; | ||||
| Assess | ||||||
| The GR-Maturation Complex: Glucocorticoid Receptor in complex with Hsp90 and co-chaperone p23 |
Heteromer P04150; Q15185; | 2×ATP; 2×MG; 1×DEX; | ||||
| Assess | ||||||
| Cryo-EM structure of Hsp90:FKBP51:p23 closed-state complex |
Heteromer Q13451; Q15185; | 2×ANP; | ||||
| Assess | ||||||
| Cryo-EM structure of Hsp90:p23 closed-state complex |
Heteromer Q15185; | 2×ANP; | ||||
| Assess | ||||||
| Human CDC37-HSP90 docking model based on NMR |
Heteromer Q16543; | |||||
| Assess | ||||||
| Crystal structure of the CHIP U-box E3 ubiquitin ligase |
Heteromer Q9WUD1; | 3×SO4; | ||||
| Assess | ||||||
| NMR structure of the second TPR domain of the human RPAP3 protein in complex with HSP90 peptide DTS… |
Heteromer Q9H6T3; | |||||
| Assess | ||||||
| Full length Tah1 bound to HSP90 peptide SRMEEVD |
Heteromer P25638; | 1×CL; | ||||
| Assess | ||||||
| AIP TPR domain in complex with human Hsp90 peptide |
Heteromer O00170; | 1×SO4; | ||||
| Assess | ||||||
| Full length Tah1 bound to yeast PIH1 and HSP90 peptide SRMEEVD |
Heteromer P25638; P38768; | 1×GOL; | ||||
| Assess | ||||||
| Second TPR of Spaghetti (RPAP3) bound to HSP90 peptide SRMEEVD |
Heteromer Q9H6T3; | |||||
| Assess | ||||||
| Solution structure of the TPR domain from Protein phosphatase 5 in complex with Hsp90 derived pepti… |
Heteromer P53041; | |||||
| Assess | ||||||
| First TPR of Spaghetti (RPAP3) bound to HSP90 peptide SRMEEVD |
Heteromer Q9H6T3; | |||||
| Assess | ||||||
| Crystal Structure of Human MC-HSP90 in C2221 Space Group | homo-6-mer | 6×SO4; | ||||
| Assess | ||||||
| Crystal Structure of Human MC-HSP90 in P21 space group | homo-6-mer | 6×SO4; | ||||
| Assess | ||||||
| human Hsp90_MC domain structure | homo-2-mer | 3×DMS; 2×GOL; | ||||
| Assess | ||||||
| human Hsp90_MC domain structure | homo-2-mer | 2×MDC; | ||||
| Assess | ||||||
| human Hsp90_MC domain structure | homo-2-mer | |||||
| Assess | ||||||
| HSP90 N-terminal domain in complex with 1-{4-[(2R)-1-(5-chloro-2,4-dihydroxybenzoyl)pyrrolidin-2-yl… | homo-2-mer | 2×BD0; 1×PO4; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-domain L107 mutant in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-… | homo-2-mer | 2×6FJ; | ||||
| Assess | ||||||
| Crystal structure of human HSP90 in intermediate state | homo-2-mer | 2×EDO; | ||||
| Assess | ||||||
| Crystal structure of human HSP90 in complex with compound 4 | homo-2-mer | 2×MG; 2×Q9O; | ||||
| Assess | ||||||
| Crystal structure of novel inhibitor bound with Hsp90 | homo-2-mer | 2×6TN; | ||||
| Assess | ||||||
| Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp9… | homo-2-mer | 2×BZ8; 2×MG; | ||||
| Assess | ||||||
| Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp9… | homo-2-mer | 2×YI0; 2×MG; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-Domain in complex with Indazole derivative | homo-2-mer | 2×9EK; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | homo-2-mer | 2×2A9; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | homo-2-mer | 2×2A7; | ||||
| Assess | ||||||
| Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp9… | homo-2-mer | 2×6QM; 2×MG; | ||||
| Assess | ||||||
| Novel, potent small molecule inhibitors of the molecular chaperone Hsp90 discovered through structu… | homo-2-mer | 2×CT5; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | homo-2-mer | 2×SO4; 2×XQI; | ||||
| Assess | ||||||
| Inhibition of the HSP90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorc… | homo-2-mer | 4×MG; 2×SO4; 2×2GG; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo… | homo-2-mer | 2×6FF; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-(5-Bromo-2,4-dihydroxy-phe… | homo-2-mer | 2×6DL; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | homo-2-mer | 2×VXX; | ||||
| Assess | ||||||
| 4,5 Diaryl Isoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of … | homo-2-mer | 2×2GJ; | ||||
| Assess | ||||||
| Dynamic Undocking and the Quasi-Bound State as tools for Drug Design | homo-2-mer | 2×IQ5; 4×SO4; | ||||
| Assess | ||||||
| Novel, potent small molecule inhibitors of the molecular chaperone Hsp90 discovered through structu… | homo-2-mer | 2×BSM; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | homo-2-mer | 4×SO4; 2×XQ0; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | homo-2-mer | 2×CL; 2×ADE; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | homo-2-mer | 2×2D4; | ||||
| Assess | ||||||
| Dynamic Undocking and the Quasi-Bound State as tools for Drug Design | homo-2-mer | 2×IEE; 6×SO4; | ||||
| Assess | ||||||
| Crystal structures of HSP90 and the compound Ganetespid in the "closed" conformation | homo-2-mer | 2×TUH; 2×MG; | ||||
| Assess | ||||||
| Crystal structure of Hsp90 with fragment 42-C03 | homo-2-mer | 2×42C; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | homo-2-mer | 2×2FY; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | homo-2-mer | 2×MG; 2×2D3; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | homo-2-mer | 2×2K4; 2×CL; | ||||
| Assess | ||||||
| 4,5 Diaryl Isoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of … | homo-2-mer | 2×2EQ; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | homo-2-mer | 2×2AE; | ||||
| Assess | ||||||
| Crystal Structure of Apo Hsp90-alpha N-domain L107A mutant | homo-2-mer | |||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-domain in complex with 5-(2,4-Dihydroxy-phenyl)-4-(2-fluoro-phen… | homo-2-mer | 2×6G7; | ||||
| Assess | ||||||
| Complex of HSP90 ATPase domain with tropane derived inhibitors | homo-2-mer | 2×99B; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-(2,4-Dihydroxy-phenyl)-4-(… | homo-2-mer | 2×6DL; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-domain in complex with N-Butyl-5-[4-(2-fluoro-phenyl)-5-oxo-4,5-… | homo-2-mer | 2×6GC; | ||||
| Assess | ||||||
| HSP90 in complex with N-Butyl-5-[4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-… | homo-2-mer | 2×6GC; 2×DMS; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-domain in complex with 2,4-Dihydroxy-N-methyl-5-(5-oxo-4-o-tolyl… | homo-2-mer | 2×6GW; | ||||
| Assess | ||||||
| Crystal structure of Hsp90 with fragment 37-D04 | homo-2-mer | 2×37D; | ||||
| Assess | ||||||
| Structure of HSP90 bound with a novel fragment | homo-2-mer | 2×MO8; | ||||
| Assess | ||||||
| Crystal structure of Hsp90 with fragment Z064 | homo-2-mer | 2×Z64; | ||||
| Assess | ||||||
| Structure of HSP90 with small molecule inhibitor bound | homo-2-mer | 2×2DL; | ||||
| Assess | ||||||
| Targetting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo [2,3-d] pyrimidine Hsp90 inhi… | homo-2-mer | 2×42C; | ||||
| Assess | ||||||
| Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor | homo-2-mer | 2×H05; | ||||
| Assess | ||||||
| Structure of HSP90 bound with a noval fragment. | homo-2-mer | 2×MOJ; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-domain in complex 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1… | homo-2-mer | 2×6GV; | ||||
| Assess | ||||||
| Crystal structure of Hsp90 with fragments 37-D04 and 42-C03 | homo-2-mer | 2×42C; 2×37D; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | homo-2-mer | 4×SO4; 2×2EC; | ||||
| Assess | ||||||
| Complex of HSP90 ATPase domain with tropane derived inhibitors | homo-2-mer | 2×592; | ||||
| Assess | ||||||
| HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "CLOSED" CONFORMATION | homo-2-mer | |||||
| Assess | ||||||
| Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor | homo-2-mer | 2×6LV; | ||||
| Assess | ||||||
| Complex of HSP90 ATPase domain with tropane derived inhibitors | homo-2-mer | 2×99A; | ||||
| Assess | ||||||
| Crystal structure of Human Hsp90 with S36 | homo-2-mer | 2×S36; | ||||
| Assess | ||||||
| HSP90 complexed with A943037 | homo-2-mer | 2×A94; | ||||
| Assess | ||||||
| Hsp90 alpha ATPase domain with bound small molecule fragment | homo-2-mer | 2×DMS; 2×LGA; | ||||
| Assess | ||||||
| Middle Domain of Human HSP90 Alpha | monomer | |||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in compl… | monomer | 1×A12; 2×MG; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in compl… | monomer | 1×CMP; 2×MG; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in compl… | monomer | 2×MG; 1×ADP; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in compl… | monomer | 1×ANP; 2×MG; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in compl… | monomer | 1×A12; 2×MG; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in compl… | monomer | 1×CMP; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in compl… | monomer | 1×APC; 2×MG; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in compl… | monomer | 1×APC; 1×MG; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with AMPCPP | monomer | 1×MG; 1×APC; | ||||
| Assess | ||||||
| Structure of HSP90 with small molecule inhibitor bound | monomer | 1×XJX; | ||||
| Assess | ||||||
| Hsp90-alpha ATPase domain in complex with 2-Amino-4-ethylthio-6-methyl-1,3,5-triazine | monomer | 1×B2J; | ||||
| Assess | ||||||
| Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxypheny… | monomer | 1×3RR; 1×PO4; | ||||
| Assess | ||||||
| Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibit… | monomer | 1×FU7; 3×PO4; | ||||
| Assess | ||||||
| Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxypheny… | monomer | 1×3RQ; 1×PO4; | ||||
| Assess | ||||||
| HSP90 N-terminal domain in complex with 4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)benzene-1,3-diol | monomer | 1×PFT; | ||||
| Assess | ||||||
| HSP90 N-terminal domain in complex with (1R)-2-(5-chloro-2,4-dihydroxybenzoyl)-N-ethylisoindoline-1… | monomer | 1×1RC; 1×PO4; | ||||
| Assess | ||||||
| Hsp90 alpha N-terminal domain in complex with a macrocyclic inhibitor | monomer | 1×VHC; 1×MG; | ||||
| Assess | ||||||
| Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone | monomer | 1×PYU; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | monomer | 1×MG; 1×ANP; | ||||
| Assess | ||||||
| Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxypheny… | monomer | 1×3RP; | ||||
| Assess | ||||||
| Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone | monomer | 1×PY9; | ||||
| Assess | ||||||
| Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibit… | monomer | 1×FU5; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in compl… | monomer | 1×MG; 1×ADP; | ||||
| Assess | ||||||
| Hsp90 alpha N-terminal domain in complex with a macrocyclic inhibitor | monomer | 1×MES; 1×VHA; | ||||
| Assess | ||||||
| Hsp90 alpha N-terminal domain in complex with an inhibitor Ro4919127 | monomer | 1×B2T; | ||||
| Assess | ||||||
| 3-(5-chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as Inhibitors of the Hsp90 Molecular Chape… | monomer | 1×2DD; | ||||
| Assess | ||||||
| Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibit… | monomer | 1×WOE; | ||||
| Assess | ||||||
| Synthesis of Benzoquinone-Ansamycin-Inspired Macrocyclic Lactams from Shikimic Acid | monomer | 1×VJ6; 1×MG; | ||||
| Assess | ||||||
| Human Hsp90 in complex with 17-desmethoxy-17-N,N-Dimethylaminoethylamino-Geldanamycin | monomer | 1×KOS; 2×MPD; 2×ACY; | ||||
| Assess | ||||||
| 3-(5-chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as Inhibitors of the Hsp90 Molecular Chape… | monomer | 1×2D7; | ||||
| Assess | ||||||
| Structure of HSP90 with small molecule inhibitor bound | monomer | 1×XDK; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with AMPCP | monomer | 1×MG; 1×A12; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with AMPPNP | monomer | 1×ANP; 1×MG; | ||||
| Assess | ||||||
| HSP90 N-terminal domain bound to ACP | monomer | 1×ACP; 1×MG; | ||||
| Assess | ||||||
| Discovery of Benzisoxazoles as Potent Inhibitors of Chaperone Hsp90 | monomer | 1×CXZ; | ||||
| Assess | ||||||
| Human Hsp90-alpha ATPase domain bound to Radicicol | monomer | 1×RDC; | ||||
| Assess | ||||||
| Structure of HSP90 with NMS-E973 inhibitor bound | monomer | 1×9UN; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in compl… | monomer | 1×AN2; 1×MG; | ||||
| Assess | ||||||
| Crystal Structure of human HSP90alpha complexed with dihydroxyphenylpyrazoles | monomer | 1×4BC; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with ADP | monomer | 1×MG; 1×ADP; | ||||
| Assess | ||||||
| Cryogenic Human Hsp90a-NTD bound to BIIB021 | monomer | 1×94M; 2×MG; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with cAMP | monomer | 1×CMP; | ||||
| Assess | ||||||
| Structure of HSP90 with small molecule inhibitor bound | monomer | 1×WOE; | ||||
| Assess | ||||||
| Structure of HSP90 with small molecule inhibitor bound | monomer | 1×T5M; | ||||
| Assess | ||||||
| HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG | monomer | 1×MG; 1×ADP; | ||||
| Assess | ||||||
| HSP90 N-terminal domain bound to ANP | monomer | 1×ANP; 1×MG; | ||||
| Assess | ||||||
| Hsp90 alpha N-terminal domain in complex with a macrocyclic inhibitor, CH5164840 | monomer | 1×VHE; | ||||
| Assess | ||||||
| Heat Shock Protein 90 Bound to CS312 | monomer | 1×4ES; | ||||
| Assess | ||||||
| GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN-BINDING DOMAIN | monomer | 1×GDM; | ||||
| Assess | ||||||
| Structure of HSP90 with small molecule inhibitor bound | monomer | 1×MG; 1×ADP; | ||||
| Assess | ||||||
| structure of HSP90 with an inhibitor bound | monomer | 1×XKL; | ||||
| Assess | ||||||
| Hsp90 N-terminal domain bound to ATP | monomer | 1×ATP; 1×MG; | ||||
| Assess | ||||||
| HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN" CONFORMATION | monomer | |||||
| Assess | ||||||
| Structure of HSP90 with small molecule inhibitor bound | monomer | 1×XJG; | ||||
| Assess | ||||||
| Structure of HSP90 with small molecule inhibitor bound | monomer | 1×C0Y; | ||||
| Assess | ||||||
| Human HSP90 alpha ATP Binding Domain, ATP-lid open conformation, R60A | monomer | |||||
| Assess | ||||||
| Human HSP90 alpha ATP Binding Domain, ATP-lid closed conformation, R46A | monomer | |||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in compl… | monomer | 1×M0U; | ||||
| Assess | ||||||
| Crystal structure of Hsp90-alpha N-terminal domain in complex with 4-(3-isopropyl-4-(4-(1-methyl-1H… | monomer | 1×9J0; | ||||
| Assess | ||||||
| HSP90 N-terminal domain bound to AGS | monomer | 1×AGS; 1×MG; | ||||
| Assess | ||||||
| HSP90 in complex with KW-2478 | monomer | 1×ET3; | ||||
| Assess | ||||||
| Crystal structure of Hsp90-alpha N-terminal domain in complex with 2-(4-Hydroxy-cyclohexylamino)-4-… | monomer | 1×YUK; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with JMC31 | monomer | 1×M0U; | ||||
| Assess | ||||||
| HSP90 in complex with Debio0932 | monomer | 1×EOR; 1×GOL; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in compl… | monomer | 1×M0U; | ||||
| Assess | ||||||
| Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures | monomer | 1×NLZ; 1×CL; | ||||
| Assess | ||||||
| Hsp90 alpha N-terminal domain in complex with an inhibitor CH5015765 | monomer | 1×GOL; 1×B2X; 1×MG; | ||||
| Assess | ||||||
| The Crystal Structure of HSP 90-alpha from Biortus. | monomer | 4×GOL; 2×EDO; | ||||
| Assess | ||||||
| Hsp90-alpha N-domain bound to NEACA | monomer | 1×N5A; 2×MG; | ||||
| Assess | ||||||
| Hsp90-alpha bound to PU-11-trans | monomer | 1×KFY; | ||||
| Assess | ||||||
| Hsp90-alpha N-domain bound to NEOCA | monomer | 1×N5O; 1×MG; | ||||
| Assess | ||||||
| Hsp90-alpha N-domain bound to NECA | monomer | 1×NEC; | ||||
| Assess | ||||||
| Crystal Structures of human HSP90alpha complexed with dihydroxyphenylpyrazoles | monomer | 1×4BC; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A | monomer | 1×MG; 1×CL; | ||||
| Assess | ||||||
| Room-temperature Human Hsp90a-NTD bound to adenine | monomer | 1×ADE; | ||||
| Assess | ||||||
| Room-temperature Human Hsp90a-NTD bound to EC144 | monomer | 1×7PP; | ||||
| Assess | ||||||
| Hsp90 alpha N-terminal domain in complex with an inhibitor CH4675194 | monomer | 1×B2K; | ||||
| Assess | ||||||
| Cryogenic Human Hsp90a-NTD bound to adenine | monomer | 1×ADE; | ||||
| Assess | ||||||
| Room-temperature Human Hsp90a-NTD bound to BIIB021 | monomer | 1×94M; 1×MG; | ||||
| Assess | ||||||
| Crystal structure of human HSP90alpha complexed with dihydroxyphenylpyrazoles | monomer | 1×43P; | ||||
| Assess | ||||||
| Structure of Hsp90 NTD with a GRP94-selective resorcinylic inhibitor. | monomer | 1×D57; 6×MG; 1×EDO; | ||||
| Assess | ||||||
| Cryogenic Human Hsp90a-NTD bound to N6M | monomer | 1×N6M; | ||||
| Assess | ||||||
| Structure-based Discovery of a New Class of Hsp90 Inhibitors | monomer | 1×AB4; | ||||
| Assess | ||||||
| HSP90 N-terminal domain in complex with 4-chloro-6-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbony… | monomer | 1×4CD; 1×DMS; | ||||
| Assess | ||||||
| Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor | monomer | 1×T62; | ||||
| Assess | ||||||
| Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp9… | monomer | 1×YI5; | ||||
| Assess | ||||||
| Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures | monomer | 1×NL8; 1×CL; | ||||
| Assess | ||||||
| Structure insights into mechanisms of ATP hydrolysis and the activation of human Hsp90 | monomer | |||||
| Assess | ||||||
| Hsp90 alpha N-terminal domain in complex with a tricyclic inhibitor | monomer | 1×GOL; 1×WHA; | ||||
| Assess | ||||||
| Hsp90-alpha S52A bound to PU-11-trans | monomer | 1×KFY; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-Domain in complex with Resorcinol derivative | monomer | 1×2EQ; | ||||
| Assess | ||||||
| Cryogenic Human Hsp90a-NTD bound to EC144 | monomer | 1×7PP; 1×MG; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R | monomer | 1×MG; 1×CL; | ||||
| Assess | ||||||
| Room-temperature Human Hsp90a-NTD bound to N6M | monomer | 1×N6M; | ||||
| Assess | ||||||
| HSP90 in complex with NVP-AUY922 | monomer | 1×2GJ; 1×MG; | ||||
| Assess | ||||||
| Cryogenic apo Human Hsp90a-NTD | monomer | |||||
| Assess | ||||||
| Hsp90-alpha ATPase domain in complex with (4-Hydroxyphenyl)morpholin-4-yl methanone | monomer | 1×MG; 1×0OY; | ||||
| Assess | ||||||
| Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) | monomer | 1×MG; 1×CL; | ||||
| Assess | ||||||
| Room-temperature apo Human Hsp90a-NTD | monomer | |||||
| Assess | ||||||
| Correlation between chemotype-dependent binding conformations of HSP90 alpha/beta and isoform selec… | monomer | 1×2LC; | ||||
| Assess | ||||||
| Hsp90-alpha N-domain bound to NPCA | monomer | |||||
| Assess | ||||||
| Hsp90 alpha N-terminal domain in complex with an aminotriazine fragment molecule | monomer | 1×MG; 1×B2J; | ||||
| Assess | ||||||
| HSP90 in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydrox… | monomer | 1×6FF; | ||||
| Assess | ||||||
| HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-3-YL)- BENZENE-1,2-DIOL | monomer | 1×4BH; | ||||
| Assess | ||||||
| HSP90A N-terminal domain in complex with BIIB021 | monomer | 1×94M; | ||||
| Assess | ||||||
| Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demon… | monomer | 1×2Q9; | ||||
| Assess | ||||||
| Crystal Structure of the N-terminal domain of an HSP90 in the presence of an the inhibitor ganetesp… | monomer | 1×TUH; | ||||
| Assess | ||||||
| Crystal structure of Human Hsp90 with JR9 | monomer | 1×JR9; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-Domain in complex with Indazole derivative | monomer | 1×9RZ; 2×DMS; | ||||
| Assess | ||||||
| Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90… | monomer | 1×40Y; 2×GOL; | ||||
| Assess | ||||||
| Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demon… | monomer | 1×FGH; | ||||
| Assess | ||||||
| Crystal Structure of Benzamide SNX-1321 bound to Hsp90 | monomer | 1×SD1; | ||||
| Assess | ||||||
| Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor | monomer | 1×IK9; | ||||
| Assess | ||||||
| Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone | monomer | 1×MG; 1×ZZ3; | ||||
| Assess | ||||||
| structure of HSP90 with an inhibitor bound | monomer | 1×50Q; | ||||
| Assess | ||||||
| Human Hsp90-alpha with 9-Butyl-8-(4-methoxy-benzyl)-9H-purin-6-ylamine | monomer | 1×PU4; | ||||
| Assess | ||||||
| Structure of HSP90 with an inhibitor bound | monomer | 1×VHD; | ||||
| Assess | ||||||
| Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demon… | monomer | 1×2QA; | ||||
| Assess | ||||||
| Identification of novel HSP90 / isoform selective inhibitors using structure-based drug design. Dem… | monomer | 1×2R6; | ||||
| Assess | ||||||
| HSP 90 in complex with Ganetespib | monomer | 1×TUH; | ||||
| Assess | ||||||
| Human Hsp90-alpha with 8-(2,5-dimethoxy-benzyl)-2-fluoro-9H-purin-6-ylamine | monomer | 1×PU2; | ||||
| Assess | ||||||
| Human Hsp90-alpha with 9-Butyl-8-(2,5-dimethoxy-benzyl)-9H-purin-6-ylamine | monomer | 1×PU7; | ||||
| Assess | ||||||
| Human Hsp90-alpha with 8-(2-chloro-3,4,5-trimethoxy-benzyl)-9-pent-4-ylnyl-9H-purin-6-ylamine | monomer | 1×PU9; | ||||
| Assess | ||||||
| Human Hsp90-alpha with 8-(2-chloro-3,4,5-trimethoxy-benzyl)-2-fluoro-9-pent-4-ylnyl-9H-purin-6-ylam… | monomer | 1×PU1; | ||||
| Assess | ||||||
| Structure of human Hsp90-alpha bound to the potent water soluble inhibitor PU-DZ8 | monomer | 1×DZ8; | ||||
| Assess | ||||||
| Hsp90 inhibitor desolvation as a rationale to steer on-rates and impact residence time | monomer | 1×H0T; | ||||
| Assess | ||||||
| Human Hsp90-alpha with 8-Benzo[1,3]dioxol-,5-ylmethyl-9-butyl-9H-purin-6-ylamine | monomer | 1×PU6; | ||||
| Assess | ||||||
| Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone | monomer | 1×DMS; 1×ZZ3; | ||||
| Assess | ||||||
| Estimation of relative drug-target residence times by random acceleration molecular dynamics simula… | monomer | 1×SO4; 1×C8W; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | monomer | 1×SO4; 1×2KU; | ||||
| Assess | ||||||
| Dynamic Undocking and the Quasi-Bound State as tools for Drug Design | monomer | 2×SO4; 1×TQL; | ||||
| Assess | ||||||
| Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone | monomer | 1×ZZ5; | ||||
| Assess | ||||||
| Hsp90 alpha N-terminal domain in complex with an inhibitor Ro1127850 | monomer | 1×B2L; | ||||
| Assess | ||||||
| Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone | monomer | 1×ZZ6; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | monomer | 1×XQK; 1×XQI; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | monomer | 1×MG; 1×XQK; 1×ZZ3; | ||||
| Assess | ||||||
| Estimation of relative drug-target residence times by random acceleration molecular dynamics simula… | monomer | 1×B5Q; | ||||
| Assess | ||||||
| Human Hsp90-alpha with 9-Butyl-8-(2-chloro-3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine | monomer | 1×PU8; | ||||
| Assess | ||||||
| Human Hsp90-alpha with 9-Butyl-8-(2,5-dimethoxy-benzyl)-2-fluoro-9H-purin-6-ylamine | monomer | 1×PU0; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | monomer | 1×2GA; | ||||
| Assess | ||||||
| Human Hsp90-alpha with 8-Benzo[1,3]dioxol-,5-ylmethyl-9-butyl-2-fluoro-9H-purin-6-ylamine | monomer | 1×PUX; | ||||
| Assess | ||||||
| Human Hsp90-alpha with 8-(2,5-dimethoxy-benzyl)-2-fluoro-9-pent-9H-purin-6-ylamine | monomer | 1×PUZ; | ||||
| Assess | ||||||
| Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone | monomer | 1×MG; 1×ZZ2; | ||||
| Assess | ||||||
| HUMAN HSP90 WITH 5-(5-CHLORO-2,4-DIHYDROXY-PHENYL)-4-PIPERAZIN-1-YL- 2H-PYRAZOLE-3-CARBOXYLIC ACID … | monomer | 1×2E1; | ||||
| Assess | ||||||
| Dipyridamole binds to the N-terminal domain of human Hsp90A | monomer | 1×H9F; 2×CL; 2×MG; | ||||
| Assess | ||||||
| Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone | monomer | 1×ZZ4; | ||||
| Assess | ||||||
| Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone | monomer | 1×2KL; | ||||
| Assess | ||||||
| HSP90 inhibitors and drugs from fragment and virtual screening | monomer | |||||
| Assess | ||||||
| Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibit… | monomer | 1×FU3; | ||||
| Assess | ||||||
| HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4-METHANESULPHONYL-BENZYL)- PIERAZIN-1-YL)-1H-PYRAZOL-3-YL)-BENZ… | monomer | 1×2D9; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-domain in complex with 5-(5-Bromo-2,4-dihydroxy-phenyl)-4-(2-flu… | monomer | 1×6DL; | ||||
| Assess | ||||||
| Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FS7 | monomer | 1×9ZC; | ||||
| Assess | ||||||
| Structure-Activity Relationships in purine-based inhibitor binding to HSP90 isoforms | monomer | |||||
| Assess | ||||||
| Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor PU-H54 | monomer | 1×P54; | ||||
| Assess | ||||||
| Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor JX1 | monomer | 1×JX1; | ||||
| Assess | ||||||
| Hsp90a NTD K58R bound reversibly to sulfonyl fluoride 6 | monomer | 1×Q2D; 1×K; 1×NA; | ||||
| Assess | ||||||
| Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ2 | monomer | 1×FJ2; | ||||
| Assess | ||||||
| Crystal structure of Human Hsp90 with FS6 | monomer | 1×8CU; | ||||
| Assess | ||||||
| Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor capable of significantly decreas… | monomer | 1×06T; | ||||
| Assess | ||||||
| Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows ext… | monomer | 1×06J; | ||||
| Assess | ||||||
| Human heat-shock protein 90 (HSP90) in complex with {4-[3-(2,4-dihydroxy-5-isopropyl-phenyl)-5-thio… | monomer | 1×819; | ||||
| Assess | ||||||
| Hsp90 alpha inhibitor | monomer | 1×OJ3; | ||||
| Assess | ||||||
| Crystal structure of Human Hsp90 with FS4 | monomer | 1×8CR; | ||||
| Assess | ||||||
| Hsp90a NTD covalently bound to sulfonyl fluoride probe 1 at K58 | monomer | 1×Q2J; | ||||
| Assess | ||||||
| Heat Shock Protein 90 Bound to CS302 | monomer | 1×4EP; 3×GOL; | ||||
| Assess | ||||||
| Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ1 | monomer | 1×FJ1; | ||||
| Assess | ||||||
| Hsp90a NTD K58R bound reversibly to sulfonyl fluoride 5 | monomer | 1×Q2A; | ||||
| Assess | ||||||
| Estimation of relative drug-target residence times by random acceleration molecular dynamics simula… | monomer | 1×PU1; | ||||
| Assess | ||||||
| Hsp90a N-terminal inhibitor | monomer | 1×ONJ; | ||||
| Assess | ||||||
| Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibit… | monomer | 1×0TM; | ||||
| Assess | ||||||
| Crystal structure of Human Hsp90 with FS3 | monomer | 1×8CO; | ||||
| Assess | ||||||
| Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90… | monomer | 1×40X; 1×GOL; | ||||
| Assess | ||||||
| Hsp90a N-terminal inhibitor | monomer | 1×ONG; | ||||
| Assess | ||||||
| Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90… | monomer | 1×40W; | ||||
| Assess | ||||||
| Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ5 | monomer | 1×FJ5; | ||||
| Assess | ||||||
| Heat Shock Protein 90 Bound to CS311 | monomer | 1×4ER; | ||||
| Assess | ||||||
| Crystal structure of Human Hsp90 with RL1 | monomer | 1×RL1; | ||||
| Assess | ||||||
| Crystal Structure of Benzamide Tetrahydro-4H-carbazol-4-one bound to Hsp90 | monomer | 1×SNX; | ||||
| Assess | ||||||
| Structure of HSP90 with small molecule inhibitor bound | monomer | 1×MG; 1×DMS; 1×LGA; 1×MT0; | ||||
| Assess | ||||||
| Hsp90a NTD covalently bound to sulfonyl fluoride 5 at K58 | monomer | 1×Q2A; | ||||
| Assess | ||||||
| Heat Shock Protein 90 Bound to CS319 | monomer | 1×4EU; 1×GOL; | ||||
| Assess | ||||||
| Structure of human Hsp90-alpha bound to resorcinylic inhibitor BnIm | monomer | 1×9QY; 2×FMT; 1×EDO; 1×MG; 1×NA; | ||||
| Assess | ||||||
| Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ6 | monomer | 1×FJS; | ||||
| Assess | ||||||
| Heat Shock Protein 90 Bound to CS318 | monomer | 1×4ET; 1×GOL; | ||||
| Assess | ||||||
| Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demon… | monomer | 1×2Q8; | ||||
| Assess | ||||||
| Heat Shock Protein 90 Bound to CS307 | monomer | 1×4EQ; | ||||
| Assess | ||||||
| Heat Shock Protein 90 Bound to CS320 | monomer | 1×4EV; | ||||
| Assess | ||||||
| Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90… | monomer | 1×40Z; 1×GOL; | ||||
| Assess | ||||||
| Structure of HSP90 with small molecule inhibitor bound | monomer | 1×GOL; 1×L81; | ||||
| Assess | ||||||
| Human Hsp90-alpha with 9-Butyl-8-(3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine | monomer | 1×PU3; | ||||
| Assess | ||||||
| Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate… | monomer | 1×7F9; 1×SO4; | ||||
| Assess | ||||||
| Heat Shock Protein 90 Bound to CS301 | monomer | 1×4EO; | ||||
| Assess | ||||||
| Human Hsp90-alpha with 9-Butyl-8-(3-trimethoxy-benzyl)-9H-purin-6ylamine | monomer | 1×PU5; | ||||
| Assess | ||||||
| Hsp90 in complex with 5-(2,4-Dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazole-3-th… | monomer | 1×G5E; 1×SO4; | ||||
| Assess | ||||||
| Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate… | monomer | 1×7FX; 1×SO4; | ||||
| Assess | ||||||
| Correlation between chemotype-dependent binding conformations of HSP90 alpha/beta and isoform selec… | monomer | 1×E0G; 3×GOL; | ||||
| Assess | ||||||
| Estimation of relative drug-target residence times by random acceleration molecular dynamics simula… | monomer | 1×SO4; 1×C4N; | ||||
| Assess | ||||||
| Crystal structure of Human Hsp90 with RL3 | monomer | 1×RL3; | ||||
| Assess | ||||||
| Structure of human Hsp90-alpha bound to the potent water soluble inhibitor PU-H71 | monomer | 1×H71; | ||||
| Assess | ||||||
| HSP90 in complex with SNX-2112 | monomer | 1×E0G; | ||||
| Assess | ||||||
| Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibit… | monomer | 1×2N6; | ||||
| Assess | ||||||
| Structure of HSP90 with small molecule inhibitor bound | monomer | 1×C0P; | ||||
| Assess | ||||||
| Estimation of Protein-Ligand Unbinding Kinetics Using Non-Equilibrium Targeted Molecular Dynamics S… | monomer | 1×D4W; | ||||
| Assess | ||||||
| HSP90 WITH indole derivative | monomer | 1×70M; | ||||
| Assess | ||||||
| HSP90 WITH indazole derivative | monomer | 1×70Z; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-domain Bound to the Inhibitor NVP-HSP990 | monomer | 1×990; | ||||
| Assess | ||||||
| Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-p… | monomer | 1×05S; 1×DMS; | ||||
| Assess | ||||||
| Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker… | monomer | 1×06H; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha Apo N-domain | monomer | |||||
| Assess | ||||||
| Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ4 | monomer | 1×FJ4; | ||||
| Assess | ||||||
| Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 3-(4-Hydroxy-phenyl)-1H-indazol-6-ol | monomer | 1×HH6; 1×SO4; | ||||
| Assess | ||||||
| Discovery of Benzisoxazoles as Potent Inhibitors of Chaperone Hsp90 | monomer | 1×BXZ; | ||||
| Assess | ||||||
| Estimation of relative drug-target residence times by random acceleration molecular dynamics simula… | monomer | 1×P4A; 2×SO4; | ||||
| Assess | ||||||
| Crystal structure of Human Hsp90 with FS2 | monomer | 1×8CF; | ||||
| Assess | ||||||
| Human Heat Shock Protein 90 bound to 6-Hydroxy-3-(3-methyl-benzyl)-1H-indazole-5-carboxylic acid me… | monomer | 1×9R8; | ||||
| Assess | ||||||
| Crystal Structure of HSP90 with N-Aryl-benzimidazolone II | monomer | 1×MEY; | ||||
| Assess | ||||||
| Crystal structure of Human Hsp90 with S46 | monomer | 1×S46; | ||||
| Assess | ||||||
| Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ5 | monomer | 1×8DU; | ||||
| Assess | ||||||
| HSP90 complexed with A143571 and A516383 | monomer | 1×A13; 1×A51; | ||||
| Assess | ||||||
| Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ6 | monomer | 1×FJ6; | ||||
| Assess | ||||||
| Crystal structure of Human Hsp90 with X29 | monomer | 1×X29; | ||||
| Assess | ||||||
| Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ3 | monomer | 1×FJ3; | ||||
| Assess | ||||||
| HSP90 N-TERMINAL DOMAIN with pochoxime B | monomer | 2×DMS; 1×JZC; | ||||
| Assess | ||||||
| HSP90 in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-N-furan-2-yl… | monomer | 1×6FJ; | ||||
| Assess | ||||||
| HSP90 complexed with A917985 | monomer | 1×A91; | ||||
| Assess | ||||||
| Estimation of relative drug-target residence times by random acceleration molecular dynamics simula… | monomer | 1×BAW; | ||||
| Assess | ||||||
| Crystal Structure of HSP90 with N-Aryl-benzimidazolone I | monomer | 1×MEX; | ||||
| Assess | ||||||
| Crystal Structure of Hsp90-alpha N-domain Bound to the Inhibitor NVP-HSP990 | monomer | 1×3JC; | ||||
| Assess | ||||||
| Estimation of relative drug-target residence times by random acceleration molecular dynamics simula… | monomer | 1×BA8; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR166475 | monomer | 1×73Z; | ||||
| Assess | ||||||
| HSP90 WITH indazole derivative | monomer | 1×70K; | ||||
| Assess | ||||||
| Estimation of relative drug-target residence times by random acceleration molecular dynamics simula… | monomer | 1×C3Z; 1×SO4; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR200323. | monomer | 1×72K; | ||||
| Assess | ||||||
| Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor | monomer | 1×TV2; | ||||
| Assess | ||||||
| HSP90 N-TERMINAL DOMAIN with pochoxime A | monomer | 1×DMS; 1×JZB; | ||||
| Assess | ||||||
| Structure of HSP90 with small molecule inhibitor bound | monomer | 1×DMS; 1×MT0; | ||||
| Assess | ||||||
| Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor | monomer | 1×W2D; | ||||
| Assess | ||||||
| Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor | monomer | 1×HAJ; | ||||
| Assess | ||||||
| Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 6-Hydroxy-3-(3-methyl-benzyl)-1H-indazol… | monomer | 1×EFU; 1×SO4; | ||||
| Assess | ||||||
| Crystal Structure of HSP90 with VER-49009 | monomer | 1×BSM; | ||||
| Assess | ||||||
| Estimation of relative drug-target residence times by random acceleration molecular dynamics simula… | monomer | 1×C4K; | ||||
| Assess | ||||||
| Structure of human Hsp90-alpha bound to the potent water soluble inhibitor PU-H64 | monomer | 1×H64; | ||||
| Assess | ||||||
| Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 3-Cyclohexyl-2-(6-hydroxy-1H-indazol-3-y… | monomer | 1×EFT; | ||||
| Assess | ||||||
| Estimation of relative drug-target residence times by random acceleration molecular dynamics simula… | monomer | 1×DMS; 1×C4T; 1×SO4; | ||||
| Assess | ||||||
| HSP90 WITH indazole derivative | monomer | 1×70N; | ||||
| Assess | ||||||
| Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor | monomer | 1×G3R; | ||||
| Assess | ||||||
| HSP90 WITH indazole derivative | monomer | 1×70O; | ||||
| Assess | ||||||
| HSP90 WITH indazole derivative | monomer | 1×70L; | ||||
| Assess | ||||||
| HSP90 complexed with A56322 | monomer | 1×A56; | ||||
| Assess | ||||||
| Tricyclic series of Hsp90 inhibitors | monomer | 1×YK9; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003492875 | monomer | 1×73S; | ||||
| Assess | ||||||
| Tricyclic series of Hsp90 inhibitors | monomer | 1×YKE; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003498614A. | monomer | 1×72Y; | ||||
| Assess | ||||||
| Tricyclic series of Hsp90 inhibitors | monomer | 1×YKJ; | ||||
| Assess | ||||||
| Tricyclic series of Hsp90 inhibitors | monomer | 1×YJW; | ||||
| Assess | ||||||
| Tricyclic series of Hsp90 inhibitors | monomer | 1×YKI; | ||||
| Assess | ||||||
| Tricyclic series of Hsp90 inhibitors | monomer | 1×YKC; | ||||
| Assess | ||||||
| Tricyclic series of Hsp90 inhibitors | monomer | 1×YJW; 1×YJX; | ||||
| Assess | ||||||
| Tricyclic series of Hsp90 inhibitors | monomer | 1×YJX; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR567530 | monomer | 1×73J; | ||||
| Assess | ||||||
| Tricyclic series of Hsp90 inhibitors | monomer | 1×YKB; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003643501 | monomer | 1×73Y; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR148019. | monomer | 1×74E; | ||||
| Assess | ||||||
3 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8ffv.1.B | monomer | 0.77 | 1×ATP; | 100.00 | ||
| Assess | ||||||
| 7kw7.1.B | monomer | 0.75 | 100.00 | |||
| Assess | ||||||
| 8u1n.1.A | homo-2-mer | 0.69 | 2×ATP; | 82.66 | ||
| Assess | ||||||
3 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 8ffv.1.B | monomer | 0.75 | 1×ATP; | 100.00 | |
| Assess | ||||||
| Isoform 2 | 7kw7.1.B | monomer | 0.74 | 100.00 | ||
| Assess | ||||||
| Isoform 2 | 8u1n.1.A | homo-2-mer | 0.68 | 2×ATP; | 82.63 | |
| Assess | ||||||